Purple Biotech Ltd. announced it is advancing NT219, a novel drug aimed at overcoming tumor resistance to therapy, into a Phase 2 clinical trial for patients with recurrent/metastatic squamous cell ...

A quadriplegic patient with a 1.5-year-old deep tunneling wound switched from packing the wound with impregnated gauze, to ...

SAN DIEGO and CALGARY, AB, Feb. 19, 2025 /PRNewswire/ -- Oncolytics Biotech (ONCY) ® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, ...

- Astellas and Vir Biotechnology to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - Adam Pearson, Chief Strategy Officer, Astellas"Astellas is proud to have ...

The life sciences industry is experiencing transformative shifts driven by technological innovation and urgent global health needs. AAA Biotech, a leading provider of premium research reagents, is ...

The National Academies of Sciences, Engineering, and Medicine will convene an ad hoc study Committee on Biotechnology Capabilities for National Security Needs--Leveraging Advances in Transdisciplinary ...

Please provide your email address to receive an email when new articles are posted on . A clinical-stage biotechnology company will advance a novel autologous chimeric antigen receptor T-cell therapy ...

- Astellas and Vir Biotechnology (VIR) to co-develop and co-commercialize VIR-5500 through a sharing of expenses and revenues - - Astellas to lead commercialization of VIR-5500 in the U.S. with Vir ...

Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer By Astellas Pharma ...